<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03757013</url>
  </required_header>
  <id_info>
    <org_study_id>CC-10004-PSOR-021</org_study_id>
    <secondary_id>U1111-1218-9791</secondary_id>
    <nct_id>NCT03757013</nct_id>
  </id_info>
  <brief_title>A Study to Assess Benefits of Apremilast in Patients With Moderate to Severe Chronic Plaque Psoriasis Followed by Dermatologists Under Real Life Settings in France</brief_title>
  <acronym>REALIZE</acronym>
  <official_title>Real Life Data for Otezla Evidence: Assessing Benefits of Apremilast in Patients With Moderate to Severe Chronic Plaque Psoriasis Followed by Dermatologists Under Real Life Settings in France</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      REALIZE study will include a representative sample of 500 patients with moderate to severe&#xD;
      plaque psoriasis for whom the treating dermatologist has decided to begin apremilast&#xD;
      treatment in accordance with the local label reimbursement criteria. Patients may be enrolled&#xD;
      into the study up to 4 weeks after starting the study treatment.&#xD;
&#xD;
      REALIZE is a longitudinal, multicenter, observational study under real life settings in&#xD;
      patients with moderate to severe chronic plaque psoriasis after failure or contra-indication&#xD;
      or intolerance to other systemic therapy including ciclosporin, methotrexate, or phototherapy&#xD;
      UVA + psoralen (PUVA therapy).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible patients will be identified and invited to enroll from approximately 100&#xD;
      dermatologists in France practicing in public hospitals (or private clinics) or private&#xD;
      practice. Patients will be followed over 12 months after initiation of apremilast or until&#xD;
      discontinuation of apremilast whatever the earlier. Given the observational nature of the&#xD;
      study, apremilast dosing and duration will be at the sole discretion of the treating&#xD;
      dermatologist, in accordance with the local label and daily clinical practice. Patient care&#xD;
      will follow routine clinical practice, involving regular follow-up visits, without any&#xD;
      mandatory visit. In daily practice, patients are usually seen by their treating dermatologist&#xD;
      every 6 months. In this study, patients will be followed up at most 12 months after&#xD;
      apremilast initiation.&#xD;
&#xD;
      During this study, it is expected to collect data at inclusion (enrolment visit) and around 6&#xD;
      months and 12 months after apremilast initiation, on electronic case report forms (eCRF) by&#xD;
      the dermatologist after performing a visit around 6 and 12 months to evaluate the treatment&#xD;
      response following the apremilast initiation.&#xD;
&#xD;
      Due to the observational nature of the study, the study protocol does not require any&#xD;
      specific tests or additional examinations. All assessments will be recorded in the electronic&#xD;
      case report form (eCRF) according to the normal practice of the treating dermatologist.&#xD;
      Self-questionnaires will be filled by the patient when visiting his/her dermatologist.&#xD;
&#xD;
      Total duration of the study is 2 years and 6 months, which includes an enrollment period of 1&#xD;
      year and 6 months and a follow up period of up to 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 25, 2018</start_date>
  <completion_date type="Actual">September 10, 2021</completion_date>
  <primary_completion_date type="Actual">July 21, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with Patient Benefit Index score (PBI-S) ≥1 at 6 months after initiation of apremilast.</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>The PBI-S questionnaire for skin diseases is a validated instrument to assess treatment needs and benefits in patients with skin diseases. It comprises 23 items on patient-relevant therapy needs and benefits.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with PBI-S (range 0-4) at 6 months after apremilast initiation</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>The PBI-S questionnaire for skin diseases is a validated instrument to assess treatment needs and benefits in patients with skin diseases. It comprises 23 items on patient-relevant therapy needs and benefits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with PBI-S=4 at 6 months after apremilast initiation</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>The PBI-S questionnaire for skin diseases is a validated instrument to assess treatment needs and benefits in patients with skin diseases. It comprises 23 items on patient-relevant therapy needs and benefits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence Rate</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>The adherence rate will be defined as the percentage of patients pursuing the treatment with apremilast at 12 months after the initiation of apremilast.. The calculation will take into account the patients having started and discontinued apremilast within 4 weeks before the enrolment visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients substituting apremilast</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>The percentage of patients substituting apremilast by a biologic will be estimated by the Kaplan Meier method. The date of origin will be defined as the date apremilast has been started.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dermatology Life Quality Index (DLQI)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>DLQ is a 10-item validated questionnaire used in a wide range of dermatological conditions and across a wide range of disease severity as a quality of life instrument. It covers a variety of health dimensions, including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. The recall period is 7 days. Each item is graded on a Likert scale of 0-3, which gives an overall score ranging from 0 to 30 where lower scores mean better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with DLQI ≤ 5</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>DLQ is a 10-item validated questionnaire used in a wide range of dermatological conditions and across a wide range of disease severity as a quality of life instrument. It covers a variety of health dimensions, including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. The recall period is 7 days. Each item is graded on a Likert scale of 0-3, which gives an overall score ranging from 0 to 30 where lower scores mean better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving DLQI 0/1</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>DLQ is a 10-item validated questionnaire used in a wide range of dermatological conditions and across a wide range of disease severity as a quality of life instrument. It covers a variety of health dimensions, including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. The recall period is 7 days. Each item is graded on a Likert scale of 0-3, which gives an overall score ranging from 0 to 30 where lower scores mean better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in DLQI score from M0 to M6 and M12</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>DLQ is a 10-item validated questionnaire used in a wide range of dermatological conditions and across a wide range of disease severity as a quality of life instrument. It covers a variety of health dimensions, including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. The recall period is 7 days. Each item is graded on a Likert scale of 0-3, which gives an overall score ranging from 0 to 30 where lower scores mean better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with improvement in DLQI ≥ 5 points between M0 and M6, M12</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>DLQ is a 10-item validated questionnaire used in a wide range of dermatological conditions and across a wide range of disease severity as a quality of life instrument. It covers a variety of health dimensions, including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. The recall period is 7 days. Each item is graded on a Likert scale of 0-3, which gives an overall score ranging from 0 to 30 where lower scores mean better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Satisfaction Questionnaire for Medication (TSQM9)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>TSQM-9 is a 9-item validated self-administered questionnaire used to evaluate the patient's overall satisfaction with study treatment. The TSQM-9 consists of 8 items that make up 3 specific scales (effectiveness, side effects, convenience) and one global satisfaction scale. Scale scores are transformed into scores from 0 to 100 with higher scores representing higher satisfaction in that domain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with sPGA 0 or 1</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>sPGA static physician global assessment is defined as single-item-5-point categorized scale reflecting the physician's assessment of psoriasis severity. This scale ranges from 0 to 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in sPGA from baseline to M6 and M12</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>sPGA static physician global assessment is defined as single-item-5-point categorized scale reflecting the physician's assessment of psoriasis severity. This scale ranges from 0 to 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of BSA (%BSA) involved at M0, M6, M12</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>BSA is the measurement of the body area involved in relation to the whole body surface</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in % BSA from M0 to M6, M12</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>BSA is the measurement of the body area involved in relation to the whole body surface</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psoriasis Area Severity Index (PASI) at M0, M6, M12</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>PASI is a common clinical tool used to measure the severity and extent of psoriasis. PASI score is a composite score grading the severity of psoriasis in four body regions according to erythema, scaling, and thickness, and the total area of skin affected. The final composite score ranges from 0 to 72, with a higher score indicating a greater severity of psoriasis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PASI from M0 to M6, M12</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>PASI is a common clinical tool used to measure the severity and extent of psoriasis. PASI score is a composite score grading the severity of psoriasis in four body regions according to erythema, scaling, and thickness, and the total area of skin affected. The final composite score ranges from 0 to 72, with a higher score indicating a greater severity of psoriasis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving PASI50 at M6, M12</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>PASI is a common clinical tool used to measure the severity and extent of psoriasis. PASI score is a composite score grading the severity of psoriasis in four body regions according to erythema, scaling, and thickness, and the total area of skin affected. The final composite score ranges from 0 to 72, with a higher score indicating a greater severity of psoriasis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving PASI75 at M6, M12.</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>PASI is a common clinical tool used to measure the severity and extent of psoriasis. PASI score is a composite score grading the severity of psoriasis in four body regions according to erythema, scaling, and thickness, and the total area of skin affected. The final composite score ranges from 0 to 72, with a higher score indicating a greater severity of psoriasis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (AEs)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Number of participants with adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of disease</measure>
    <time_frame>Baseline</time_frame>
    <description>Duration of disease will be defined as the length of time the disease has been present, indication by months of years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of areas of plaque psoriasis</measure>
    <time_frame>Baseline</time_frame>
    <description>The number of area of plaque psoriasis will be defined by the number of area observed by the Investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of chronic psoriasis involved</measure>
    <time_frame>Baseline</time_frame>
    <description>Types if chronic psoriasis, scalp, palmoplantar, genital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of lines of previous systemic treatments</measure>
    <time_frame>Baseline</time_frame>
    <description>Number of lines of previous systemic treatments will be described by one line, two lines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of systemic therapy previously administered</measure>
    <time_frame>Baseline</time_frame>
    <description>The type of systemic therapies includes corticosteroids, topical, other classification of medications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of previous chronic psoriasis treatment</measure>
    <time_frame>Baseline</time_frame>
    <description>The duration of previous treatment will be described in months, years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of motivations of the prescription of apremilast</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Motivations will be described by the number of patients with lack of response or intolerance or patient's dissatisfaction regarding the previous treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of motivations of the prescription of apremilast</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Motivations will be described by the percentage of patients with lack of response or intolerance or patient's dissatisfaction regarding the previous treatment.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">453</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Patients treated with Apremilast</arm_group_label>
    <description>Patients with moderate to severe chronic plaque psoriasis after failure or contra-indication or intolerance to other systemic therapy including ciclosporin, methotrexate, or phototherapy UVA + psoralen (PUVA therapy).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apremilast</intervention_name>
    <description>Apremilast</description>
    <arm_group_label>Patients treated with Apremilast</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with moderate to severe plaque psoriasis for whom the treating dermatologist has&#xD;
        decided to begin apremilast treatment in accordance with the local label reimbursement&#xD;
        criteria. Patients may be enrolled into the study up to 4 weeks after starting the study&#xD;
        treatment.&#xD;
&#xD;
        All eligible patients will be included in the safety population in consecutive order based&#xD;
        on the date of the non-opposition form.&#xD;
&#xD;
        However, only patients who have completed 6 (± 1) months of treatment will be included in&#xD;
        the reference analysis population&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female aged at least 18 years&#xD;
&#xD;
          -  Patient with a diagnosis of stable moderate to severe chronic plaque psoriasis&#xD;
&#xD;
          -  For whom the treating dermatologist has made the decision to initiate apremilast&#xD;
             treatment in accordance with the local label and reimbursement criteria i.e. a history&#xD;
             of failure or contra-indication or intolerance to other systemic therapy including&#xD;
             ciclosporin, methotrexate, or phototherapy UVA + psoralen (PUVA therapy)&#xD;
&#xD;
          -  Patient having started apremilast up to 4 weeks before the enrolment visit for&#xD;
             treatment of moderate to severe chronic plaque psoriasis even if apremilast has been&#xD;
             stopped before inclusion in the study&#xD;
&#xD;
          -  Patient literate and willing to fill in questionnaires&#xD;
&#xD;
          -  Non-opposition form signed by the investigator indicating that the patient received&#xD;
             information about the study, and orally agreed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient who refuses to participate in the study or is unable to give his/her oral&#xD;
             consent&#xD;
&#xD;
          -  Patient having participated in an interventional study in the last 30 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Private Practice, Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint-Joseph Clinic, Angouleme</name>
      <address>
        <city>Angouleme</city>
        <zip>16000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice, Antibes</name>
      <address>
        <city>Antibes</city>
        <zip>06600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice 2, Antony</name>
      <address>
        <city>Antony</city>
        <zip>92160</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice 2, Arcachon</name>
      <address>
        <city>Arcachon</city>
        <zip>33120</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice, Argenteuil</name>
      <address>
        <city>Argenteuil</city>
        <zip>95100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice, Aubière</name>
      <address>
        <city>Aubière</city>
        <zip>63170</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice, Auch</name>
      <address>
        <city>Auch</city>
        <zip>32000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auxerre Hospital</name>
      <address>
        <city>Auxerre</city>
        <zip>89000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henri Duffaut Hospital</name>
      <address>
        <city>Avignon Cedex 9</city>
        <zip>84902</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice, Besançon</name>
      <address>
        <city>Besançon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reims-Bezannes Polyclinic 2</name>
      <address>
        <city>Bezannes</city>
        <zip>51430</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reims-Bezannes Polyclinic 3</name>
      <address>
        <city>Bezannes</city>
        <zip>51430</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reims-Bezannes Polyclinic</name>
      <address>
        <city>Bezannes</city>
        <zip>51430</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice, Biarritz</name>
      <address>
        <city>Biarritz</city>
        <zip>64200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice, Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Docteur Duchenne Hospital 2</name>
      <address>
        <city>Boulogne-sur-Mer</city>
        <zip>62321</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Docteur Duchenne Hospital</name>
      <address>
        <city>Boulogne-sur-Mer</city>
        <zip>62321</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice, Bègles</name>
      <address>
        <city>Bègles</city>
        <zip>33130</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice 2, Caen</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice 3, Caen</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice, Caen</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice, Cannes</name>
      <address>
        <city>Cannes</city>
        <zip>06400</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice 2, Chalons-en-Champagne</name>
      <address>
        <city>Chalons-en -Champagne</city>
        <zip>51000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice, Chalons-en-Champagne</name>
      <address>
        <city>Chalons-en-Champagne</city>
        <zip>51000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chalons-en-Champagne Hospital</name>
      <address>
        <city>Chalons-en-Champagne</city>
        <zip>51005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice, Chamalières</name>
      <address>
        <city>Chamalières</city>
        <zip>63400</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trousseau Hospital</name>
      <address>
        <city>Chambray-Les-Tours Cedex</city>
        <zip>37171</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Métropole Savoie Hospital</name>
      <address>
        <city>Chambéry</city>
        <zip>73000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice 2, Chartres</name>
      <address>
        <city>Chartres</city>
        <zip>28000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice, Chartres</name>
      <address>
        <city>Chartres</city>
        <zip>28000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Sud Francilien Hospital</name>
      <address>
        <city>Corbeil Essonnes</city>
        <zip>91100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GH de Dax, Dax</name>
      <address>
        <city>Dax</city>
        <zip>40107</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice 2, Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice 3, Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice, Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice, Dole</name>
      <address>
        <city>Dole</city>
        <zip>39100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Victor Jousselin Hospital</name>
      <address>
        <city>Dreux</city>
        <zip>28102</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emile Durkheim Hospital - Saint Jean Health Center</name>
      <address>
        <city>Epinal Cedex</city>
        <zip>88021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice, Essey-les-Nancy</name>
      <address>
        <city>Essey-les-Nancy</city>
        <zip>54270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Golfe de St-Tropez Clinic</name>
      <address>
        <city>Gassin</city>
        <zip>83580</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice 2, Joue les Tours</name>
      <address>
        <city>Joue les Tours</city>
        <zip>37300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice 3, Joue les Tours</name>
      <address>
        <city>Joue les Tours</city>
        <zip>37300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice, Joue les Tours</name>
      <address>
        <city>Joue les Tours</city>
        <zip>37300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice, L'Union</name>
      <address>
        <city>L'Union</city>
        <zip>31240</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice 2, La Teste-de-Buch</name>
      <address>
        <city>La Teste-de-Buch</city>
        <zip>33260</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice, La Teste-de-Buch</name>
      <address>
        <city>La Teste-de-Buch</city>
        <zip>33260</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice, La Valette du Var</name>
      <address>
        <city>La Valette du Var</city>
        <zip>83160</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice, La Varenne Saint Hilaire</name>
      <address>
        <city>La Varenne Saint Hilaire</city>
        <zip>94210</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice 2, Laval</name>
      <address>
        <city>Laval</city>
        <zip>53000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice, Laval</name>
      <address>
        <city>Laval</city>
        <zip>53000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice, Le Mans</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mans Hospital 2</name>
      <address>
        <city>Le Mans</city>
        <zip>72037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mans Hospital</name>
      <address>
        <city>Le Mans</city>
        <zip>72037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice, Le-Bourget-du-Lac</name>
      <address>
        <city>Le-Bourget-du-Lac</city>
        <zip>73370</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice, Lille</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice 2, Luce</name>
      <address>
        <city>Luce</city>
        <zip>28110</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice, Luce</name>
      <address>
        <city>Luce</city>
        <zip>28110</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice, Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69002</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edouard Herriot Hospital</name>
      <address>
        <city>Lyon</city>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice 2, Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69006</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice 4, Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice, Martigues</name>
      <address>
        <city>Martigues</city>
        <zip>13500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Annecy Genevois Hospital, Metz Tessy</name>
      <address>
        <city>Metz Tessy</city>
        <zip>74370</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice, Meudon-la-Forêt</name>
      <address>
        <city>Meudon-la-Forêt</city>
        <zip>92360</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice, Muret</name>
      <address>
        <city>Muret</city>
        <zip>31600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hotel Dieu Hospital, Dermatologic Clinic</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice, Narbonne</name>
      <address>
        <city>Narbonne</city>
        <zip>11100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice, Nevers</name>
      <address>
        <city>Nevers</city>
        <zip>58000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice 2, Nice</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice 3, Nice</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice, Nogent-Le-Rotrou</name>
      <address>
        <city>Nogent-Le-Rotrou</city>
        <zip>28400</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice, Orléans</name>
      <address>
        <city>Orléans</city>
        <zip>45000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice, Paris</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice 2, Paris</name>
      <address>
        <city>Paris</city>
        <zip>75006</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice 3, Paris</name>
      <address>
        <city>Paris</city>
        <zip>75008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice 4, Paris</name>
      <address>
        <city>Paris</city>
        <zip>75009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice 5, Paris</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice, Pontarlier</name>
      <address>
        <city>Pontarlier</city>
        <zip>25300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice, Pontoise</name>
      <address>
        <city>Pontoise</city>
        <zip>95300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice, Quimper</name>
      <address>
        <city>Quimper</city>
        <zip>29000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHI de Cornouaille - Laennec</name>
      <address>
        <city>Quimper</city>
        <zip>29107</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mathilde II Clinic</name>
      <address>
        <city>Rouen</city>
        <zip>76100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice, Saint-Etienne</name>
      <address>
        <city>Saint-Etienne</city>
        <zip>42000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint-Etienne Hospital</name>
      <address>
        <city>St Priest en Jarez</city>
        <zip>42277</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice, Torcy</name>
      <address>
        <city>Torcy</city>
        <zip>77200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BCRM Toulon - HIA Saint-Anne</name>
      <address>
        <city>Toulon Cedex 9</city>
        <zip>83800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice, Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nord Franche-Comté Hospital</name>
      <address>
        <city>Trevenans</city>
        <zip>90400</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valence Hospital 2</name>
      <address>
        <city>Valence</city>
        <zip>26953</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valence Hospital 3</name>
      <address>
        <city>Valence</city>
        <zip>26953</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valence Hospital</name>
      <address>
        <city>Valence</city>
        <zip>26953</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jacques Lacarin Hospital</name>
      <address>
        <city>Vichy</city>
        <zip>03201</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>September 25, 2018</study_first_submitted>
  <study_first_submitted_qc>November 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 28, 2018</study_first_posted>
  <last_update_submitted>December 1, 2021</last_update_submitted>
  <last_update_submitted_qc>December 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Plaque Psoriasis</keyword>
  <keyword>Apremilast</keyword>
  <keyword>France</keyword>
  <keyword>CC-10004</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apremilast</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03757013
org study id: CC-10004-PSOR-021
secondary id: U1111-1218-9791
nct id: NCT03757013
lead sponsor: 
has dmc: No
is fda regulated drug: Yes
is fda regulated device: No
is us export: No
REALIZE study will include a representative sample of 500 patients with moderate to severe
      plaque psoriasis for whom the treating dermatologist has decided to begin apremilast
      treatment in accordance with the local label reimbursement criteria. Patients may be enrolled
      into the study up to 4 weeks after starting the study treatment.

      REALIZE is a longitudinal, multicenter, observational study under real life settings in
      patients with moderate to severe chronic plaque psoriasis after failure or contra-indication
      or intolerance to other systemic therapy including ciclosporin, methotrexate, or phototherapy
      UVA + psoralen (PUVA therapy).
Eligible patients will be identified and invited to enroll from approximately 100
      dermatologists in France practicing in public hospitals (or private clinics) or private
      practice. Patients will be followed over 12 months after initiation of apremilast or until
      discontinuation of apremilast whatever the earlier. Given the observational nature of the
      study, apremilast dosing and duration will be at the sole discretion of the treating
      dermatologist, in accordance with the local label and daily clinical practice. Patient care
      will follow routine clinical practice, involving regular follow-up visits, without any
      mandatory visit. In daily practice, patients are usually seen by their treating dermatologist
      every 6 months. In this study, patients will be followed up at most 12 months after
      apremilast initiation.

      During this study, it is expected to collect data at inclusion (enrolment visit) and around 6
      months and 12 months after apremilast initiation, on electronic case report forms (eCRF) by
      the dermatologist after performing a visit around 6 and 12 months to evaluate the treatment
      response following the apremilast initiation.

      Due to the observational nature of the study, the study protocol does not require any
      specific tests or additional examinations. All assessments will be recorded in the electronic
      case report form (eCRF) according to the normal practice of the treating dermatologist.
      Self-questionnaires will be filled by the patient when visiting his/her dermatologist.

      Total duration of the study is 2 years and 6 months, which includes an enrollment period of 1
      year and 6 months and a follow up period of up to 1 year.
observational model: Cohort
time perspective: Retrospective
measure: Proportion of patients with Patient Benefit Index score (PBI-S) ≥1 at 6 months after initiation of apremilast.
time frame: Up to 6 months
description: The PBI-S questionnaire for skin diseases is a validated instrument to assess treatment needs and benefits in patients with skin diseases. It comprises 23 items on patient-relevant therapy needs and benefits.
measure: Proportion of subjects with PBI-S (range 0-4) at 6 months after apremilast initiation
time frame: Up to 6 months
description: The PBI-S questionnaire for skin diseases is a validated instrument to assess treatment needs and benefits in patients with skin diseases. It comprises 23 items on patient-relevant therapy needs and benefits.
measure: Proportion of patients with PBI-S=4 at 6 months after apremilast initiation
time frame: Up to 6 months
description: The PBI-S questionnaire for skin diseases is a validated instrument to assess treatment needs and benefits in patients with skin diseases. It comprises 23 items on patient-relevant therapy needs and benefits
measure: Adherence Rate
time frame: Up to 12 months
description: The adherence rate will be defined as the percentage of patients pursuing the treatment with apremilast at 12 months after the initiation of apremilast.. The calculation will take into account the patients having started and discontinued apremilast within 4 weeks before the enrolment visit.
measure: Percentage of patients substituting apremilast
time frame: Up to 24 months
description: The percentage of patients substituting apremilast by a biologic will be estimated by the Kaplan Meier method. The date of origin will be defined as the date apremilast has been started.
measure: Dermatology Life Quality Index (DLQI)
time frame: Up to 24 months
description: DLQ is a 10-item validated questionnaire used in a wide range of dermatological conditions and across a wide range of disease severity as a quality of life instrument. It covers a variety of health dimensions, including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. The recall period is 7 days. Each item is graded on a Likert scale of 0-3, which gives an overall score ranging from 0 to 30 where lower scores mean better quality of life.
measure: Proportion of patients with DLQI ≤ 5
time frame: Up to 24 months
description: DLQ is a 10-item validated questionnaire used in a wide range of dermatological conditions and across a wide range of disease severity as a quality of life instrument. It covers a variety of health dimensions, including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. The recall period is 7 days. Each item is graded on a Likert scale of 0-3, which gives an overall score ranging from 0 to 30 where lower scores mean better quality of life.
measure: Proportion of patients achieving DLQI 0/1
time frame: Up to 24 months
description: DLQ is a 10-item validated questionnaire used in a wide range of dermatological conditions and across a wide range of disease severity as a quality of life instrument. It covers a variety of health dimensions, including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. The recall period is 7 days. Each item is graded on a Likert scale of 0-3, which gives an overall score ranging from 0 to 30 where lower scores mean better quality of life.
measure: Change in DLQI score from M0 to M6 and M12
time frame: Up to 12 months
description: DLQ is a 10-item validated questionnaire used in a wide range of dermatological conditions and across a wide range of disease severity as a quality of life instrument. It covers a variety of health dimensions, including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. The recall period is 7 days. Each item is graded on a Likert scale of 0-3, which gives an overall score ranging from 0 to 30 where lower scores mean better quality of life.
measure: Proportion of patients with improvement in DLQI ≥ 5 points between M0 and M6, M12
time frame: Up to 12 months
description: DLQ is a 10-item validated questionnaire used in a wide range of dermatological conditions and across a wide range of disease severity as a quality of life instrument. It covers a variety of health dimensions, including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. The recall period is 7 days. Each item is graded on a Likert scale of 0-3, which gives an overall score ranging from 0 to 30 where lower scores mean better quality of life.
measure: Treatment Satisfaction Questionnaire for Medication (TSQM9)
time frame: Up to 24 months
description: TSQM-9 is a 9-item validated self-administered questionnaire used to evaluate the patient's overall satisfaction with study treatment. The TSQM-9 consists of 8 items that make up 3 specific scales (effectiveness, side effects, convenience) and one global satisfaction scale. Scale scores are transformed into scores from 0 to 100 with higher scores representing higher satisfaction in that domain.
measure: Proportion of patients with sPGA 0 or 1
time frame: Up to 24 months
description: sPGA static physician global assessment is defined as single-item-5-point categorized scale reflecting the physician's assessment of psoriasis severity. This scale ranges from 0 to 4.
measure: Change in sPGA from baseline to M6 and M12
time frame: Up to 12 months
description: sPGA static physician global assessment is defined as single-item-5-point categorized scale reflecting the physician's assessment of psoriasis severity. This scale ranges from 0 to 4.
measure: Percentage of BSA (%BSA) involved at M0, M6, M12
time frame: Up to 12 months
description: BSA is the measurement of the body area involved in relation to the whole body surface
measure: Change in % BSA from M0 to M6, M12
time frame: Up to 12 months
description: BSA is the measurement of the body area involved in relation to the whole body surface
measure: Psoriasis Area Severity Index (PASI) at M0, M6, M12
time frame: Up to 12 months
description: PASI is a common clinical tool used to measure the severity and extent of psoriasis. PASI score is a composite score grading the severity of psoriasis in four body regions according to erythema, scaling, and thickness, and the total area of skin affected. The final composite score ranges from 0 to 72, with a higher score indicating a greater severity of psoriasis
measure: Change in PASI from M0 to M6, M12
time frame: Up to 12 months
description: PASI is a common clinical tool used to measure the severity and extent of psoriasis. PASI score is a composite score grading the severity of psoriasis in four body regions according to erythema, scaling, and thickness, and the total area of skin affected. The final composite score ranges from 0 to 72, with a higher score indicating a greater severity of psoriasis
measure: Proportion of patients achieving PASI50 at M6, M12
time frame: Up to 12 months
description: PASI is a common clinical tool used to measure the severity and extent of psoriasis. PASI score is a composite score grading the severity of psoriasis in four body regions according to erythema, scaling, and thickness, and the total area of skin affected. The final composite score ranges from 0 to 72, with a higher score indicating a greater severity of psoriasis
measure: Proportion of patients achieving PASI75 at M6, M12.
time frame: Up to 12 months
description: PASI is a common clinical tool used to measure the severity and extent of psoriasis. PASI score is a composite score grading the severity of psoriasis in four body regions according to erythema, scaling, and thickness, and the total area of skin affected. The final composite score ranges from 0 to 72, with a higher score indicating a greater severity of psoriasis
measure: Adverse Events (AEs)
time frame: Up to 24 months
description: Number of participants with adverse events
measure: Duration of disease
time frame: Baseline
description: Duration of disease will be defined as the length of time the disease has been present, indication by months of years.
measure: Number of areas of plaque psoriasis
time frame: Baseline
description: The number of area of plaque psoriasis will be defined by the number of area observed by the Investigator
measure: Type of chronic psoriasis involved
time frame: Baseline
description: Types if chronic psoriasis, scalp, palmoplantar, genital
measure: The number of lines of previous systemic treatments
time frame: Baseline
description: Number of lines of previous systemic treatments will be described by one line, two lines
measure: Type of systemic therapy previously administered
time frame: Baseline
description: The type of systemic therapies includes corticosteroids, topical, other classification of medications
measure: Duration of previous chronic psoriasis treatment
time frame: Baseline
description: The duration of previous treatment will be described in months, years.
measure: Number of motivations of the prescription of apremilast
time frame: Up to 24 months
description: Motivations will be described by the number of patients with lack of response or intolerance or patient's dissatisfaction regarding the previous treatment.
measure: Percentage of motivations of the prescription of apremilast
time frame: Up to 24 months
description: Motivations will be described by the percentage of patients with lack of response or intolerance or patient's dissatisfaction regarding the previous treatment.
arm group label: Patients treated with Apremilast
description: Patients with moderate to severe chronic plaque psoriasis after failure or contra-indication or intolerance to other systemic therapy including ciclosporin, methotrexate, or phototherapy UVA + psoralen (PUVA therapy).
intervention type: Drug
intervention name: Apremilast
description: Apremilast
arm group label: Patients treated with Apremilast
study pop: 
sampling method: Non-Probability Sample
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: MD
role: Study Director
affiliation: Amgen
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
country: France
url: http://www.amgentrials.com
description: AmgenTrials clinical trials website
responsible party type: Sponsor
mesh term: Psoriasis
mesh term: Apremilast